Home > Pharmaceuticals > Pharmacogenomics Market Outlook, Size to 2022 – 2030
Straits Research

Pharmacogenomics Market

Pharmacogenomics Market: Information by Product and Services (Instruments and Services), Technology (NGS and PCR), Application (CVDs) and End User (Research), and Region — Forecast till 2030

Table of Content Download Sample

Market Snapshot

market snapshot
Base Year:
Study Period:
8.47 %
Fastest Growing Market:
Asia Pacific
Largest Market:
United States

The global pharmacogenomics market size was valued at USD 5,676 USD million in 2021. It is expected to reach USD 11,798 million, growing at a CAGR of 8.47% during the forecast period (2022–2030). The popularity of pharmacogenomics (PGx) has surged, hastening developments in precision medicine. Pharmacogenomics can also help identify drug responders and non-responders, avoid side effects, and determine the proper therapeutic dose. Pharmacogenomic technologies are used extensively in numerous government programs, bolstering the industry. The FDA requires pharmacogenomic information labeling to ensure the safety and efficacy of approved medications. As a result, labeling pharmaceuticals with pharmacogenomics market data in the United States is another significant boost to market growth.

Pharmacogenomics Market Share

Get more information on this report Download Sample Report

Market Dynamics

Global Pharmacogenomics Market Drivers

Constant Demand for the Treatment of Scathing Diseases

Genomics and precision medicine have become increasingly important in treating cancer patients in the last decade due to the increased prevalence of diseases such as cancer, which has no apparent cure or treatment plan. Unlike other illnesses, cancer therapy must account for both acquired (somatic) and inherited (germline) variation, which affects a drug's efficacy and safety. Therefore, pharmacogenomic tests have been used extensively to identify treatment options. 

Increasing Concerns Regarding Adverse Drug Reactions

Physicians' adverse pharmaceutical responses remain a concern in today's global healthcare system primarily because one patient may have side effects while another obtains no benefit. Consequently, the diversity of society results in unanticipated reactions, which hinders the current healthcare market scenario. According to FDA data, 6.7 percent of hospitalized patients experienced an adverse drug reaction, with a 0.3 percent mortality rate. If these figures are correct, approximately 2,216,000 adverse drug reactions occur in hospitalized patients yearly, resulting in over 106,000 deaths.

Pharmacogenomics market solutions offer a noteworthy remedy to the issue. Pharmacogenomics aims to improve treatment outcomes by elucidating the underlying biological mechanisms and utilizing genetic contributions for customized medication.

Global Pharmacogenomics Market Restraint

High Expense of Conducting Research and Development

Pharmacogenetics studies are applicable at many phases of medication development. It is possible to analyze and identify the impact of polymorphisms on drug responsiveness. Pharmacogenetic testing can stratify patients according to their genotype and metabolizing ability in clinical investigations. As pharmacogenetics is increasingly used to guide the administration of various pharmaceuticals, the FDA has established standards for pharmaceutical companies to submit pharmacogenetic data for labeling their drug products. As a result, pharmacogenomic techniques and related research and development costs remain exceptionally high.

Segmental Analysis

The global pharmacogenomics market is segmented by products and services.

By Product

Based on product, the global market is divided into Instruments and Services.

The instruments segment owns the largest revenue share, and the segment is anticipated to grow at a rate of 8.67 % during the forecast period. The instrument/panel section is the most expensive product, which includes premium items such as next-generation sequencers, PCR heat cyclers, microarray panels, and mass spectrometers. The segment consists of molecular diagnostics and specialist pharmacogenomics test kits, responsible for a substantial portion of the market's income. Additionally, the part of consumables contributes significantly to worldwide income. Consumables, such as equipment and reagents, are ongoing expenses that must be purchased in bulk on a regular or as-needed basis.

By Technology

Based on technology, the global market is classified into PCR and NGS.

PCR segment accounts for the most significant contributor and is anticipated to grow at a rapid 8.47% CAGR during the forecast period. The polymerase chain reaction has the most critical market share in the global pharmacogenomics market's technology segment. The polymerase chain reaction is expected to grow in the future due to the irreplaceability of amplifying a small fragment of DNA. The low cost of sequencing procedures, rapid technological innovation, and increased precision and efficiency in achieving desired results.

By End-User

Based on end-user, the global market is classified into Research.

The biopharmaceutical firm's market segment is the largest due to pharmacogenomic solutions' increasing adoption and incorporation into the R&D and drug discovery pipelines. In addition, this market sector uses pharmacogenomics pharmacogenomic products and solutions in clinical trials, particularly Phase III. Consequently, there is an expanding market opportunity, and we anticipate a substantial revenue inflow by the conclusion of the projected period.

Contract Research Organizations and Molecular Diagnostics Laboratories had the second-largest global market share in sales value. This is because these facilities are well-equipped with molecular diagnostic equipment and lab units to meet the wide range of patient needs. Moreover, compared to other medical institutions, these facilities have superior infrastructure, technology benefits, and highly trained medical personnel. The rise of hospitals as end-users has accelerated, and the global pharmacogenomics market is anticipated to maintain its leading position for the foreseeable future.

Regional Analysis

The global pharmacogenomics market is primarily classified into three regions, namely The U.S., Asia-Pacific, The Middle East and Africa, and Europe.

Pharmacogenomics Market Regional Analysis

Regional Growth Insights Request Sample Pages

Regarding income, the U.S. regional market for pharmacogenomics is the largest. Some factors driving the market include the increasing prevalence of chronic diseases, such as cancer, and increased end-user awareness of the use and benefits of pharmacogenomics. Over the past decade, government and private sector funding have funded over eleven programs in the United States. 

The following is a selection of the most noteworthy projects:

  • The U.S. Pharmacogenomics Research Network, for instance, developed the Translational Pharmacogenomics Program to integrate pre-emptive pharmacogenomic testing in numerous clinical settings.
  • In addition, the 1200 Patients Project at the University of Chicago sought to determine the viability and benefit of implementing pre-emptive pharmacogenomic testing of a panel of genes. In addition, the study aimed to assess the influence of pharmacogenomics test results on prescriptions, medical decisions, and patient outcomes.

Asia-Pacific is one of the fastest-growing marketplaces in the world. Diseases such as cancer are becoming more prevalent due to increased healthcare and research in emerging nations such as Japan and India.

Cancer is one of the top reasons for disease and mortality among patients. According to a study conducted by Globocan, Asia-Pacific has one of the highest cancer prevalence rates (excluding skin cancer) globally. In addition, the market offers substantial pockets of opportunity due to government spending and the expanding penetration of genomic technologies, assisted by the emergence of pharmaceutical businesses, especially biosimilars.

Competitive Analysis

The global pharmacogenomics market’s major key players are

  • Thermo Fisher Scientific
  • Admera Health
  • Agena Biosciences Inc.
  • Illunima Inc
  • OneOme LLC
  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Dynamic DNA Laboratories
  • Personalis Inc.
  • Coriell Life Sciences
  • Phamatech Inc
  • BiogeniQ Inc.
  • Empire Genomics
  • ViennaLab Diagnostics GmbH

Recent Development

  • April 2022- Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children

Global Pharmacogenomics Market: Segmentation

By Product and Services

  • Instruments
  • Consumables
  • Services
  • Software

By Technology

  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Gel electrophoresis
  • Mass Spectrometry
  • Microarray
  • Hybridization

By Application

  • Cardiovascular disease
  • Infectious diseases
  • Oncology
  • Neurological diseases
  • Pain Management and Trauma

By End-User

  • Bio-Pharmaceutical Companies
  • Research and Academic institutes
  • Contract Research Organization and Molecular Diagnostics Labs

By Regions

  • The U.S.
  • Asia-Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions (FAQs)

Pharmacogenomics (PGx) is the study of genetic variation in drug response. The pharma industry is beginning to use this knowledge to improve drug therapies, but there are challenges that must be overcome before the benefits of pharmacogenomics can be fully realized.
Thermo Fisher Scientific, Admera Health, Agena Biosciences, Inc., Illunima, Inc, OneOme, LLC, Myriad Genetics, Inc., Quest Diagnostics, Dynamic DNA Laboratories, Personalis Inc., Coriell Life Sciences are the top players in the market
Yes, the Pharmacogenomics market is growing owing to the rising prevalence of chronic diseases, and expanding penetration of genomic technologies.
The global pharmacogenomics market size was valued at USD 5,676 USD million in 2021. It is expected to reach USD 11,798 million, growing at a CAGR of 8.47% during the forecast period (2022–2030).
Report Metric Details
Market Size USD 11,798 in Million By 2030
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Product and Services (Instruments, Services), Technology (NGS, PCR), Application (CVDs) and End User (Research)
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Thermo Fisher Scientific, Admera Health, Agena Biosciences, Inc., Illunima, Inc, OneOme, LLC, Myriad Genetics, Inc., Quest Diagnostics, Dynamic DNA Laboratories, Personalis Inc., Coriell Life Sciences, Phamatech, Inc, BiogeniQ Inc
Key Market Opportunities Government spending and the expanding penetration of genomic technologies
Price Starts From

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Nippon Becton Dickinson
Argon Medical Devices
Johnson & Johnson
Need Assistance?
+1 646 480 7505 (U.S.)
+44 208 068 9665 (U.K.)
Looking For Custom Report ?

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Check Our License Options :
Report Snapshot

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers